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liver cirrhosis, severe heart or lung failure, dia‑
betes, or malignancy). None of the subjects had 
used a proton pump inhibitor or prokinetic ther‑
apy prior to enrollment. Some individuals used 
alkalizing agents or H2 inhibitors on demand, 
but not during the 7 days before the study. In‑
formed consent was obtained from all patients, 
and the study was approved by the Institutional 
Review Board of Jagiellonian University Medi‑
cal College, Kraków, Poland.
The study groups consisted of 24 patients with 
GERD and thyroid disease (GERD ‑Th) and 36 pa‑
tients with GERD without an endocrine disorder, 
who constituted the control group. The GERD‑
‑Th group consisted of 19 patients with hypothy‑
roidism (79.17%), 4 patients with hyperthyroid‑
ism (16.67%), and 1 patient with multinodular 
goiter (4.17%). All GERD ‑Th patients were treat‑
ed for thyroid diseases and remained euthyroid.
Each participant completed the FSSG question‑
naire, and BMI and waist ‑to ‑hip ratio were calcu‑
lated. Blood cell count, fasting glucose, lipids, thy‑
rotropin, free thyroxine (FT4), and free triiodothy‑
ronine were measured. Esophagitis severity was 
assessed according to the Los Angeles scale, and 
the patients were classified into nonerosive reflux 
disease (NERD) or erosive reflux disease groups.
Statistical analysis Continuous variables were 
presented as arithmetic means and standard de‑
viations or as medians and interquartile rang‑
es (Q1–Q3). The Shapiro–Wilk test was used to 
test the normality of the variable distribution. 
The t test or Mann–Whitney test was used to as‑
sess the differences in continuous variables be‑
tween control and GERD ‑Th groups. Categorical 
variables were reported as numbers (percentages) 
and were analyzed using the χ2 test or Fisher ex‑
act test, as appropriate. Statistical analyses were 
performed using SPSS 25.0 (SPSS Inc., Chicago, 
Introduction According to the Montreal defini‑
tion, gastroesophageal reflux disease (GERD) is 
a condition presenting with persistent symptoms 
and complications that result from the reflux of 
stomach contents into the esophagus.1 The etio‑
pathogenesis of GERD includes impaired gastric 
emptying, impaired esophageal clearance, and 
dysfunction of the lower esophageal sphincter.2 
Numerous studies have demonstrated an associ‑
ation between the intensity of GERD symptoms 
and abdominal obesity, considered to be a risk 
factor for Barrett esophagus and esophageal ad‑
enocarcinoma.2-4 Esophageal acid exposure time 
and the number of refluxes correlate positively 
with body mass index (BMI).5 Some studies have 
indicated that GERD complications are associat‑
ed with arterial hypertension, insulin resistance, 
and lipid abnormalities, while the intensity of re‑
flux symptoms may be affected by metabolic syn‑
drome or diabetes.6-9
Few studies have evaluated whether thyroid 
diseases affect the clinical manifestations of 
GERD. We evaluated differences in the clinical 
course and endoscopic images of GERD between 
patients with and without thyroid disease.
Patients and methods The study included 60 pa‑
tients from the Department of Gastroenterology 
and Hepatology, University Hospital in Kraków, 
and from the Department of Internal Medicine 
and Gastroenterology, 5th Military Hospital in 
Kraków. Patients were recruited from Septem‑
ber 2017 to September 2018.
The inclusion criteria were as follows: age 
above 18  years and newly diagnosed GERD 
based on the frequency scale for the symptoms 
of GERD (FSSG) criteria.10 The exclusion crite‑
ria were pregnancy, acute diseases (such as in‑
fections, myocardial infarction, stroke, pulmo‑
nary embolism), and chronic diseases (such as 
RESEARCH LETTER
Nonerosive reflux disease is more common 
in patients with chronic thyroid disease: 
preliminary results
Małgorzata Krakowska ‑Stasiak1, Dorota Cibor2, Iwon Grys1, Tomasz Mach2, Danuta Owczarek2
1  Department of Internal Medicine and Gastroenterology, 5th Military Hospital, Kraków, Poland
2  Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Kraków, Poland
Correspondence to:
Danuta Owczarek, MD, PhD, 
Department of Gastroenterology, 
Hepatology and Infectious Diseases, 
Jagiellonian University Medical College, 
ul. Śniadeckich 5, 31-531 Kraków,  
phone: +48 12 424 73 40, Poland, 
email: owczarek@su.krakow.pl
Received: November 17, 2018.
Revision accepted: 
December 3, 2018.
Published online: December 5, 2018.
Conflict of interest: none declared.
Pol Arch Intern Med. 2018; 
128 (12): 788-790
10.20 452/pamw.4385
Copyright by Medycyna Praktyczna, 
Kraków 2018
RESEARCH LETTER NERD is more common in patients with chronic thyroid diseases. 789
Discussion Our study is among the few stud‑
ies in which the GERD diagnosis was established 
based on a validated and clinically useful scale. 
Moreover, all patients underwent gastrosco‑
py, which allowed for a detailed assessment of 
the esophageal mucosa. Our study is also one of 
the few studies to evaluate the effect of thyroid 
disease on the clinical picture of GERD.
Gastrointestinal symptoms may occasional‑
ly be the first sign of thyroid disease and a de‑
layed diagnosis evokes negative consequences.6 
Extraesophageal GERD symptoms associated 
with irritation of the posterior throat wall are 
manifested as in a thyroid disease and include 
hoarseness, coughing, dysphonia, and dyspha‑
gia.11 Savina et al12 suggested that GERD symp‑
toms in patients with hypothyroidism are associ‑
ated with disorders of gastrointestinal tract mo‑
tility rather than esophageal exposure to acid.
To date, the association between GERD and 
thyroid dysfunction has been assessed mostly in 
the context of anatomically close organs, such as 
the esophagus and thyroid, and possible thyroid 
surgery complications. Only Nomura et al6 at‑
tempted to find associations between endocrine 
Illinois, United States). A P value of less than 
0.05 was considered significant.
Results The characteristics of the study groups 
are presented in TABLE 1. There were significantly 
more women in the GERD ‑Th group compared 
with the control group. GERD ‑Th patients had 
a significantly lower waist ‑to ‑hip ratio than con‑
trols. GERD intensity as assessed by the FSSG was 
positively correlated with waist circumference (r = 
0.45, P = 0.007) and with BMI (r = 0.43, P = 0.01) 
in controls. Such correlations were not found in 
the GERD ‑Th group. Thyrotropin levels did not dif‑
fer between the groups. The highest mean FT4 lev‑
el was noted in the GERD ‑Th group rather than 
in the control group (P <0.001). None of the thy‑
roid hormone parameters were significantly asso‑
ciated with the FSSG score. The GERD ‑Th group 
demonstrated a significantly higher FSSG score, 
by an average of 3.8 points, compared with con‑
trols. GERD ‑Th patients more commonly report‑
ed a burning sensation in the throat and heart‑
burn while bending than controls (P = 0.02 and P 
= 0.01, respectively). NERD was significantly more 
in GERD ‑Th patients than in controls (TABLE 1).
TABLE 1 Characteristics of patients with gastroesophageal reflux disease and thyroid disease (GERD-Th) and 
controls





Age, y, mean (SD) 62.4 (12) 57.33 (15.78) 0.24a
Sex, female, n (%) 23 (95.8) 17 (47.2) <0.001c
BMI, kg/m2, mean (SD) 26.47 (4.8) 26.16 (4.56) 0.92a
WHR, mean (SD) 0.84 (0.07) 0.9 (0.07) <0.001a
Hemoglobin, g/dl, mean (SD) 13.68 (1.13) 13.7 (1.56) 0.56a
FG, mmol/l, median (Q1–Q3) 5.29 (4.8–5.57) 5.2 (4.8–5.6) 0.93b
TC, mmol/l, mean (SD) 5.4 (1.0) 5.3 (1.6) 0.19a
HDL -C, mmol/l, mean (SD) 1.6 (0.35) 1.4 (0.3) 0.04a
LDL -C, mmol/l, mean (SD) 3.2 (1.0) 3.4 (1.3) 0.12a
Triglycerides, mg/dl, median (Q1–Q3) 113 (86–143) 93 (73–122) 0.16b
Thyrotropin, ulU/ml, median (Q1–Q3) 1.7 (0.7–2.88) 1.25 (0.94–1.91) 0.43b
FT3, pmol/l, mean (SD) 4.26 (0.5 8) 4.61 (0.64) 0.008a
FT4, pmol/l, mean (SD) 17.63 (2.76) 14.88 (2.21) <0.001
FSSG score, mean (SD) 20.38 (7.37) 16.58 (6.58) 0.04a
NERD, n (%) 20 (83.3) 22 (61.1) 0.04c
Comorbidities
Hypertensiona, n (%) 10 (41.67) 13 (36.1) 0.48c
Lipid disordersb, n (%) 6 (25) 13 (36.1) 0.50c
Medications
LT4 substitution, n (%) 19 (79.17) 0 (0)
Antithyroid therapy, n (%) 4 (16.67) 0 (0)
a t test,   b Mann–Whitney test,   c χ2 test,   d Hypertension defined as use of antihypertensive 
drugs,   e Lipid disorders defined as use of lipid -lowering drugs
SI conversion factors: to convert hemoglobin to g/l, multiply by 10; triglycerides to mmol/l, by 0.0113.
Abbreviations: BMI, body mass index; FT3, free triiodothyronine; FT4, free thyroxine; FG, fasting glucose; FSSG, 
frequency scale for the symptoms of GERD; GERD, gastroesophageal reflux disease; HDL -C, high -density lipoprotein 
cholesterol; LDL -C, low -density lipoprotein cholesterol; LT4, levothyroxine; NERD, nonerosive reflux disease; TC, total 
cholesterol; WHR, waist -to -hip ratio
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of burning in the throat and less commonly pre‑
sented with erosive reflux disease. The results 
suggest that overweight in patients with a thy‑
roid disease is not the major risk factor favoring 
reflux symptom development. From the clinical 
point of view, it can be assumed that asking the 
patient about burning in the throat would be 
helpful in early detection of GERD in patients 
with thyroid disease.
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disorders and GERD. Our study is the first to as‑
sess clinical symptoms and endoscopic images in 
patients with GERD and thyroid disease in com‑
parison with patients without a concomitant hor‑
monal disorder.
Nomura et al6 reported a group of 111 subjects 
with adrenal cortex and thyroid disorders, acro‑
megaly, obesity, and hormonally inactive adrenal 
tumors. The authors demonstrated that obesity 
and triglyceride levels were positively correlated, 
while high ‑density lipoprotein cholesterol levels 
were negatively correlated with FSSG ‑assessed 
GERD symptoms, confirming an earlier report on 
the greater frequency of GERD in patients with 
metabolic syndrome.6 In our study, GERD ‑Th 
patients showed a tendency toward abdominal 
obesity, compared with controls. FSSG ‑assessed 
GERD symptoms correlated positively with waist 
circumference and BMI only in controls. In view 
of recent studies demonstrating the association 
between intensity of GERD symptoms and obesi‑
ty, and considering our study, it may be conclud‑
ed that overweight and obesity in patients with 
thyroid disease are not the principal risk factors 
favoring the development of reflux symptoms.
Thyrotropin levels did not differ between 
the groups, but significant differences were not‑
ed in the free thyroid hormone levels. The lack of 
a significant difference in thyrotropin levels may 
be because all GERD ‑Th patients were on therapy 
and remained euthyroid. However, a significantly 
higher FT4 level was demonstrated in the GERD‑
‑Th group than in controls. Hence, further stud‑
ies in a larger group are necessary, particularly 
in subjects with uncontrolled hormonal disor‑
ders, to explain more fully their effect on GERD.
Additionally, we did not find any correla‑
tion between thyrotropin and free thyroid hor‑
mone levels and GERD symptoms as assessed by 
the FSSG between the groups. Nomura et al6 re‑
ported similar results.
Contrary to the above study, all patients we ex‑
amined were subjected to gastroscopy, allowing 
us to assess the degree of esophagitis. The vast 
majority of the GERD ‑Th group did not present 
with esophagitis. Interestingly, GERD ‑Th pa‑
tients had higher FSSG scores compared with 
controls, which confirms the lack of correlation 
between severity of clinical symptoms and mu‑
cosal injury. A previous study demonstrated that 
diabetes in patients with GERD predisposes pa‑
tients to esophagitis.8 In contrast, thyroid dis‑
eases do not show such an association.
Our report has some limitations, such as 
a small number of patients with thyroid disease. 
Studies on a larger patient population, partic‑
ularly one with uncontrolled thyroid hormon‑
al dysfunction, would allow for a more detailed 
determination of the effect of such disorders on 
the course of GERD. The groups were not uni‑
form with respect to sex, and no posttreatment 
assessment was made.
In conclusion, patients with GERD and con‑
comitant thyroid disease complained more often 
